1.The GP view
Why this matters in first‑opinion practice
We also dug into useful GI nuggets for Monday: a pharmacokinetic paper about metoclopramide CRIs and a blinded RCT where a single FMT enema didn’t outperform diet change in chronic enteropathy. Below are the practical takeaways and how we’d use them in a busy GP setting.
- Feline blood products are logistically hard in GP. If canine fresh‑frozen plasma (FFP) can buy time for a bleeding, coagulopathic cat when a feline donor or referral isn’t realistic, that’s a useful out‑of‑hours option — but it comes with real risks.
- “Is this sepsis?” is now a more precise question. The new consensus asks for infection + dysregulated host response + organ dysfunction before you call it sepsis. That changes triage, admission wording and owner conversations.
- Anti‑NGF monoclonal antibodies remain a very useful tool for osteoarthritic patients, but recent SPC updates list very rare joint‑related adverse events. A new three‑monthly feline anti‑NGF has also been authorised in the UK, which could materially improve compliance for cats.
2.Canine plasma in cats: when, why and the real‑world risks
What the recent papers showed
What this means in practice
Monday‑morning move
If a cat is bleeding with a documented coagulopathy and your only available plasma is canine FFP, brief the owner that this is a one‑off, time‑buying xenotransfusion with reaction risk, and that you’ll monitor closely and pair it with definitive therapy.
- A single‑centre retrospective series reported eight cats (nine transfusions) given canine FFP for clinical coagulopathy; most transfusions corrected clotting tests in the short term.
- A multicentre retrospective series of 14 cats receiving canine plasma products also recorded partial or complete normalisation of PT/APTT in several cases, but two cats in that series had suspected acute transfusion reactions described as acute respiratory distress.
- Think of canine FFP as a one‑off, time‑buying bridge for secondary coagulopathies (it supplies clotting factors, not platelets). It’s useful when feline products or referral aren’t options.
- Risks are real. Cats are prone to transfusion reactions generally; xenotransfusion adds another immune mismatch. Reports recommend avoiding repeat xenotransfusions in the same patient.
- The evidence is small and retrospective, so informed owner consent and close monitoring are essential. Pair any plasma transfusion with definitive therapy (e.g. vitamin‑K for rodenticide) and escalate if needed.
3.Is sepsis actually sepsis? The updated consensus
What’s changed
Examples of organ dysfunction (practical list)
How this helps in GP
Admission prompt
Suspect infection + SIRS? Actively look for organ dysfunction — mentation, BP, lactate, acid–base, respiratory status and coagulation — before you commit to the label “sepsis.”
- Sepsis should no longer be defined simply as “SIRS + suspected infection.” The current consensus requires:
- Confirmed or strongly suspected infection,
- Evidence of a dysregulated host response (the SIRS‑type picture), and
- Evidence of organ dysfunction.
- Altered mentation
- Hypotension or need for vasopressors
- High lactate or persistent metabolic acidosis
- Respiratory dysfunction
- Coagulopathy
- Marked azotaemia or hypoglycaemia in context
- It gives clearer language for notes, referrals and owner conversations. A pyometra with fever and tachycardia isn’t automatically “septic” unless organ dysfunction is present.
- It clarifies when to escalate: if organ dysfunction is present, plan 24‑hour care and discuss referral and likely costs/prognosis with owners.
4.Anti‑NGF monoclonal antibodies: safety update and a new feline option
What changed
Putting “very rare” into perspective
Clinical nuance
Feline developments
Owner wording
“This class of drug has very rare joint‑related adverse effects listed on the UK data sheet. Most patients benefit, but we’ll monitor closely and stop treatment if we see anything concerning.”
- Librela’s UK product information (SPC) was updated to list very rare adverse effects: joint swelling, joint pain, bone and joint disorders, and soft‑tissue ossification. The VMD has reported multi‑source evidence of an association, which prompted the SPC change.
- The SPC describes these events as very rare; that classification is useful when having balanced conversations with owners. Thousands of doses have been administered globally and the majority of patients do well, but the class of drugs now carries a recorded, rare joint‑related risk.
- Many older, lean, painful dogs experience meaningful quality‑of‑life gains on anti‑NGF therapy. Be more cautious in younger dogs: prioritise diagnosis and surgical/orthopaedic options before reflexively starting long‑term anti‑NGF treatment.
- A three‑monthly feline anti‑NGF monoclonal antibody (relfovetmab / Portela) was authorised by the UK regulator very recently. It’s given subcutaneously every three months; early trial signals were encouraging, but real‑world experience in cats is still limited.
- Don’t assume dog safety signals transfer identically to cats — monitoring is ongoing.
5.Metoclopramide CRI: steady‑state timing and the idea of a loading dose
Key PK insight
Why that matters
A practical caution
Clinical pearl
If you regularly use metoclopramide CRIs, think about how you’ll manage the early‑hours pharmacology — a loading strategy could plausibly speed clinical effect, but verify exact dosing and legality before use. Always address perfusion, electrolytes (notably potassium) and the underlying cause first.
- A pharmacokinetic modelling paper found that, without a loading dose, metoclopramide CRIs may take several hours to reach steady state (authors reported an estimate around three‑plus hours).
- In regurgitating, ileus‑ridden patients, three hours is a long time to wait for motility support. The PK modelling therefore considered the concept of a small IV loading dose before starting a CRI to reach target plasma levels sooner.
- If you’re interested in adopting a loading‑dose approach, check the original PK paper and your local formularies, and consider licensing/regulatory guidance before using any specific numerical regimen in practice. Translate the concept (loading dose to shorten time to effect) into your protocols only after verifying doses with primary sources and your practice policy.
6.Faecal microbiota transplantation (FMT) in chronic enteropathy
What the RCT found
How to use this in GP
Quick check
Chronic diarrhoea? Reserve FMT enthusiasm for cases where stronger evidence supports it or as part of a study protocol; diet change remains a cornerstone.
- A blinded RCT compared a single retention‑enema FMT using fresh donor faeces versus diet change alone in dogs with chronic enteropathy.
- The trial did not demonstrate a clear clinical benefit of a single FMT enema over diet change for that population. The sample size was small, so the study doesn’t rule out benefit in other settings or with different protocols.
- For chronic diarrhoea (>3 weeks), don’t expect a single FMT enema to be a magic fix; diet trials and targeted diagnostics remain first‑line.
- Acute GI indications (e.g. severe infectious diarrhoea) may be a different scenario where FMT has more support — evidence collection is ongoing.
7.Commission‑based pay: culture, ethics and the day job
Practical thoughts from the pod
Practice move
If you’re shaping incentives, reward behaviours that protect patient welfare and team culture (reliability, client communication, teamwork) rather than revenue generated.
- Commission or production pay is uncommon across UK teams we work with. Concerns include over‑testing, pressure on owners, and skewed case selection — especially out‑of‑hours.
- The team prefers alternative rewards that encourage teamwork and reliability: bonuses for peer‑recognised hard work, missed‑break cover, outstanding client feedback, “no‑complaint” periods, and immunities to billing‑driven decisions.
8.Other practical notes from the pod
Takeaway
If you want to discuss any of these topics for your practice protocols or need a template owner consent for xenotransfusion, drop us a voice note — we love hearing how you use these ideas in the clinic.
- Pimobendan: a recent paper suggested dogs started on pimobendan pre‑clinically may reach congestive heart failure later, but survival after onset of CHF appeared shorter in that pretreated group. The nuance: earlier drug exposure may delay CHF onset, but once CHF occurs the dog may have less time left because optimal therapy is already in place. This is primarily an owner‑expectation discussion point rather than an immediate change to practice.
- Toxicology differentials: hot summers increase algal blooms. Cyanobacterial (blue‑green algae) exposures can present very sick dogs and are one of several possible causes of acute hepatic injury; leptospirosis remains an important differential in animals exposed to water and with compatible signs.
- Small, pragmatic changes in GP can make a big difference: consider canine FFP as a one‑off bridge for coagulopathic cats if no feline product is available (full owner consent and monitoring essential); use the updated sepsis framework (infection + dysregulated response + organ dysfunction) to guide escalation; be aware of very rare joint‑related SPC updates for anti‑NGF drugs and the arrival of a three‑monthly feline option; and if you use metoclopramide CRIs consider the pharmacokinetic rationale for a loading dose, but verify doses and regulatory status with primary sources before applying them.
Listen to the full episode for the discussion, context and the bits that made Charlotte and Brendan laugh.
Listen to Episode 29How was Episode 29?
Give this conversation a rating from one to five stars. Your rating helps us make more of the episodes you find useful.
